Literature DB >> 15965676

Perfluorocarbon-perfused vitrectomy: a new method for vitrectomy--a safety and feasibility study.

Hugo Quiroz-Mercado1, J Guerrero-Naranjo, R Agurto-Rivera, C Leizaola-Fernández, L Suárez-Tatá, S Murillo-López, G Reategui-Escalante, G García-Aguirre, J Fromow-Guerra.   

Abstract

PURPOSE: To evaluate the safety and feasibility of perfluorocarbon-perfused vitrectomy (PCPV) as a technique during vitrectomy for proliferative diabetic retinopathy (PDR) and rhegmatogenous retinal detachment (RRD).
METHODS: In an experimental, prospective, noncomparative and interventional study, 28 eyes of 28 patients were submitted to vitrectomy with the PCPV technique, 18 eyes with PDR and 10 with RRD. In this technique we replaced the traditional balanced saline solution (BSS) in the infusion line (conventional vitrectomy) by perfluorocarbon liquids (PCL). Some patients with PDR were treated with oxygenated PCL. Clinical evaluation, electroretinography (ERG), and endothelial cell count (ECC) were used to assess the safety of this procedure. An arbitrary grading system (grades 0-5) was used to classify the surgery and maneuvers to assess feasibility.
RESULTS: No eyes had a significant decrease in ECC, and the patients in whom we could obtain ERG postoperatively showed no significant differences from preoperative ERG. In the PDR group (using oxygenated and nonoxygenated PCL), 77.8% were graded 5/5; in the RRD group 90% were 5/5. PCPV allowed better visualization of vitreous and intraocular structures, rapid retinal reattachment, less blood in the vitreous cavity, subretinal fluid resolution, blood confinement, retinal stabilization, and easier dissection of epiretinal membranes. In all cases at least one surgical step was eliminated.
CONCLUSIONS: PCPV in humans is a safe and feasible technique. Probably in selected cases the use of PCL offers several advantages over BSS, because of their properties (gravitational forces, immiscibility with bodily fluids, and ability to transport oxygen). Prospective and comparative studies are necessary to establish formal indications and possible contraindications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15965676     DOI: 10.1007/s00417-004-1063-z

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  32 in total

Review 1.  Liquid ventilation.

Authors:  T H Shaffer; M R Wolfson; L C Clark
Journal:  Pediatr Pulmonol       Date:  1992-10

2.  Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases.

Authors:  E M Opremcak; R A Bruce; M D Lomeo; C D Ridenour; A D Letson; A J Rehmar
Journal:  Retina       Date:  2001       Impact factor: 4.256

3.  Giant retinal tears. Surgical techniques and results using perfluorocarbon liquids.

Authors:  S Chang; H Lincoff; N J Zimmerman; W Fuchs
Journal:  Arch Ophthalmol       Date:  1989-05

4.  Vitrectomy: a pars plana approach.

Authors:  R Machemer; H Buettner; E W Norton; J M Parel
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1971 Jul-Aug

5.  Ocular oxygen consumption during vitreoperfusion in the cat.

Authors:  N P Blair
Journal:  Trans Am Ophthalmol Soc       Date:  2000

6.  Experimental vitreous replacement with perfluorotributylamine.

Authors:  S Chang; N J Zimmerman; T Iwamoto; R Ortiz; D Faris
Journal:  Am J Ophthalmol       Date:  1987-01-15       Impact factor: 5.258

7.  Low viscosity liquid fluorochemicals in vitreous surgery.

Authors:  S Chang
Journal:  Am J Ophthalmol       Date:  1987-01-15       Impact factor: 5.258

8.  Surgical decompression of branch retinal vein occlusions.

Authors:  M D Osterloh; S Charles
Journal:  Arch Ophthalmol       Date:  1988-10

9.  Perfluorinated organic liquid as an intraocular oxygen reservoir for the ischemic retina.

Authors:  C A Wilson; B A Berkowitz; R Srebro
Journal:  Invest Ophthalmol Vis Sci       Date:  1995-01       Impact factor: 4.799

Review 10.  Perfluorocarbon emulsions and cardiopulmonary bypass: a technique for the future.

Authors:  B D Spiess; R P Cochran
Journal:  J Cardiothorac Vasc Anesth       Date:  1996-01       Impact factor: 2.628

View more
  8 in total

1.  Perfluorocarbon in vitreoretinal surgery and preoperative bevacizumab in diabetic tractional retinal detachment.

Authors:  J Fernando Arevalo; Martin A Serrano; Juan D Arias
Journal:  World J Diabetes       Date:  2014-10-15

2.  Proteomic analysis of vitreous biopsy techniques.

Authors:  Jessica M Skeie; Eric N Brown; Harryl D Martinez; Stephen R Russell; Emily S Birkholz; James C Folk; H Culver Boldt; Karen M Gehrs; Edwin M Stone; Michael E Wright; Vinit B Mahajan
Journal:  Retina       Date:  2012 Nov-Dec       Impact factor: 4.256

Review 3.  [Heavy liquids as intraoperative instrument in retinal surgery].

Authors:  Karl Boden; K Januschowski; P Szurman
Journal:  Ophthalmologe       Date:  2019-10       Impact factor: 1.059

4.  Perfluorocarbon-perfused 23 gauge three-dimensional vitrectomy for complicated diabetic tractional retinal detachment.

Authors:  Raul Velez-Montoya; Jose Luis Guerrero-Naranjo; Gerardo Garcia-Aguirre; Virgilio Morales-Cantón; Jans Fromow-Guerra; Hugo Quiroz-Mercado
Journal:  Clin Ophthalmol       Date:  2011-12-20

5.  Short-term perfluorocarbon liquid tamponade in choroidal melanoma endoresection.

Authors:  Hany S Hamza; Ayman G Elnahry
Journal:  Int J Retina Vitreous       Date:  2022-07-06

6.  Subretinal perfluorocarbon liquid for dissection of proliferative vitreoretinopathy.

Authors:  Jose Dalma-Weiszhausz; Valentina Franco-Cardenas; Alejandro Dalma
Journal:  J Ophthalmic Vis Res       Date:  2012-10

Review 7.  Perfluorocarbon liquid: its application in vitreoretinal surgery and related ocular inflammation.

Authors:  Qi Yu; Kun Liu; Li Su; Xin Xia; Xun Xu
Journal:  Biomed Res Int       Date:  2014-03-30       Impact factor: 3.411

8.  Outcomes of Vitrectomy Under Air for Idiopathic Macular Hole

Authors:  Murat Karaçorlu; Mümin Hocaoğlu; Işıl Sayman Muslubaş; M. Giray Ersöz; Serra Arf
Journal:  Turk J Ophthalmol       Date:  2019-12-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.